AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 152 min read$AZN

AstraZeneca, Leidos, Expeditors International: CNBC ‘Final Trades’ - Expeditors International (NYSE:EXPD)

CNBC's 'Final Trades' featured picks from Jim Lebenthal (AstraZeneca, AZN), Stephen Weiss (Leidos, LDOS), Liz Thomas (Treasuries), and Joseph Terranova (Expeditors, EXPD). AZN reported regulatory approvals and strong trial data, LDOS beat Q2 estimates and raised guidance, and EXPD also exceeded Q2 expectations. Shares of AZN, LDOS, and EXPD rose 2.3%, 3.1%, and 0.5% respectively on Monday.

Original reporting
benzinga.com
Published Sep 15, 2026, 11:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AZN
Bullish
high confidence
Mentioned
$AZN · $LDOS · $EXPD
Relevance
8/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$AZNBullishHigh
01

Why it matters

New earnings numbers and drug approval constitute primary disclosures that can move prices today.

02

Market read

Fresh earnings and regulatory news provide actionable trading signals across pharma, defense, and logistics sectors.

03

What to watch

Potential regulatory scrutiny on AstraZeneca's new therapy and macro‑economic headwinds for logistics.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

The article summarizes final trade picks from a CNBC segment, highlighting fresh earnings beats and a regulatory approval.

Company-level read

Ticker impact

$AZNBullishHigh confidence
Context

AstraZeneca secured regulatory approval for a new breast cancer treatment and reported strong Phase 3 trial data.

Expected impact

upward pressure in near term

Evidence & confidence

Approval and data are fresh, material catalysts for a large pharma.

$LDOSBullishHigh confidence
Context

Leidos posted better‑than‑expected Q2 earnings and raised FY26 guidance.

Expected impact

upward move expected

Evidence & confidence

First report of earnings numbers and guidance change.

$EXPDBullishHigh confidence
Context

Expeditors International reported Q2 earnings beat and higher sales.

Expected impact

slight upside

Evidence & confidence

Fresh earnings data for a logistics firm.

Market effects

Sector

Pharma approval may lift biotech peers; defense and logistics earnings could influence sector sentiment.

Regional

European pharma news adds upside to UK/European markets; US earnings affect broader market.

Global

Combined earnings and regulatory news provide cross‑sector momentum.

Counterpoint

What could challenge this read

If earnings guidance is overly optimistic, stocks could face pull‑back on profit‑taking.

Key entities

  • Company
    AstraZeneca

    Pharmaceutical firm with new breast cancer drug approval.

  • Company
    Leidos Holdings

    Defense contractor reporting earnings beat.

  • Company
    Expeditors International

    Logistics provider with earnings beat.

Read at source← All news

Related articles

OCT 27
$AZNHigh

T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer

The European Commission approved trastuzumab deruxtecan (T-DXd, Enhertu) for HER2-positive early breast cancer with residual disease post-neoadjuvant treatment. Approval based on DESTINY-Breast05 trial showing 53% reduced risk of recurrence/death vs ado-trastuzumab emtansine (T-DM1). AstraZeneca announced the approval.

onclive.com2 min
OCT 27
$AMGNMedAI 9/10

Imdelltra Plus Imfinzi Cut Death Risk 58% for Patients with Extensive-Stage Small Cell Lung Cancer in Interim Results

Amgen's Imdelltra (tarlatamab) plus AstraZeneca's Imfinzi (durvalumab) reduced death risk by 58% in extensive-stage small cell lung cancer patients, per interim phase 3 trial results. Median survival was 21.1 months vs. 12.7 months for Imfinzi alone. The combination is not yet approved for this use. Imdelltra is approved in the U.S. for later-line treatment. Side effects were more common with the combination.

medicaldaily.com3 min
OCT 27
$AZNMed

AstraZeneca, Daiichi Sankyo's Enhertu Wins First EU Approval In Early Breast Cancer Setting

AstraZeneca (AZN) and Daiichi Sankyo (4568.T) announced EU approval for Enhertu as a standalone post-surgical treatment for HER2-positive early breast cancer. The approval, based on the DESTINY-Breast05 trial, showed Enhertu reduced recurrence risk by 53% vs. T-DM1. AstraZeneca will pay Daiichi Sankyo a $75M milestone. AZN shares were down 0.35% in pre-market trading.

rttnews.com2 min